Plaintiff: LifeScreen Sciences LLC
Defendant: Cordis Corporation
Case Number: 6:12-cv-01024
Date Filed: December 28, 2012
Court: Texas Eastern District Court
The patent US5709704 involved in this suit is currently assigned[i] to Boston Scientific SciMed Inc. (source: Maxval’s Assignment Database). The patent entitled Blood clot filtering was issued on January 20, 1998 and expires[ii] on January 20, 2015. According to the complaint, plaintiff is the owner with rights to enforce and prosecute actions for infringement of the ‘704 patent.
About the Parties:
LifeScreen Sciences LLC has a place of business in Frisco, TX.
Cordis Corporation develops products to treat circulatory system diseases including congestive heart failure and cerebral aneurysms. Cordis is divided into five units: Cordis Cardiology focuses on cardiovascular disease diagnosis and treatment, Cordis Endovascular develops devices for endovascular and liver diseases, Biosense Webster develops medical sensor and electrophysiology technology for cardiovascular use, Conor Medsystems provides vascular drug delivery technologies and the Biologics Delivery Systems division makes cardiac mapping equipment used to improve the delivery of biological therapies. The company was founded in 1959 and operates as a subsidiary of Johnson & Johnson.
As in Complaint:
Plaintiff alleges that defendant manufactures and markets TrapEase® and OptEase® Retrieval Vena Cava Filters that infringe the methods claimed in the ‘704 patent. TrapEase Permanent Vena Cava Filter (see Fig.1) is indicated for use in the prevention of recurrent pulmonary embolism (PE) via percutaneous placement in the inferior vena cava. OptEase® Retrievable Vena Cava Filter (see Fig. 2) is the same as TrapEase Filter plus the additional option of retrieval.
[i] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.